Kidney360 · 4 Nov 2026
Projected US Government Expenditures for Dialysis Care: 2030-2040
David A. Rosenkranzh-index 1, Ryan C. McDevitt, Glenn M. Chertow, Mitchell H. Rosner, Samir M. Parikhh-index 54
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background: ESKD is one of the fastest-growing and costliest chronic conditions in the United States. We forecasted net spending by the US government through 2040 for persons with prevalent ESKD and Medicare and examined how it could change if person-years treated with hemodialysis were diverted to other treatment modalities, an earlier stage of kidney disease, or no kidney disease. Methods: We conducted a time-series observational analysis of aggregated, secondary data spanning 2002-2022 published by the US Renal Data System (USRDS). The data included all persons with CKD or ESKD with fee-for-service Medicare claims. We examined alternative scenarios in which person-years using hemodialysis are diverted to peritoneal dialysis, a kidney transplant, CKD Stages G4-5, and, in some cases, CKD Stage G3 and no kidney disease. The outcome measure was government spending, which is the sum of Medicare spending and disability benefits, net of federal tax revenue. Results: Based on trends from the last two decades, the model forecasted 9.1 million person-years with ESKD and Medicare coverage during 2030-2040 and government spending for these person-years totaling $783 billion. We found that if person-years treated with hemodialysis were diverted, then government spending could subsequently fall by $13-126 billion over this time depending on the volume of diverted person-years and the extent to which the progression of kidney disease can be slowed. Conclusions: Deliberate, evidence-based investments that shift modalities and slow progression to ESKD could subsequently lower government spending by billions of dollars while improving the lives of people with kidney disease.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Samir M. Parikh has the highest h-index among the authors (54).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.